ONO-4538 Phase II Rollover Study (ONO-4538-98)

PHASE2RecruitingINTERVENTIONAL
Enrollment

59

Participants

Timeline

Start Date

September 10, 2020

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Pan-tumor
Interventions
DRUG

ONO-4538

IV infusion over 30 minutes

DRUG

oxaliplatin

IV infusion over 2 hours

DRUG

S-1

Administered orally twice daily

DRUG

capecitabine

Administered orally twice daily

DRUG

bevacizumab

IV infusion over 30 minutes

DRUG

temozolomide

Administered orally once daily for 5 days every 28 days

Trial Locations (38)

Unknown

RECRUITING

Chiba Clinical Site1, Kashiwa

COMPLETED

Ehime Clinical Site1, Matsuyama

RECRUITING

Fukuoka Clinical Site1, Kurume

RECRUITING

Hokkaido Clinical Site1, Sapporo

RECRUITING

Hyogo Clinical Site1, Akashi

RECRUITING

Kanagawa Clinical Site1, Yokohama

RECRUITING

Oita Clinical Site1, Yufu

RECRUITING

Osaka Clinical Site1, Suita

RECRUITING

Osaka Clinical Site3, Takatsuki

RECRUITING

Saitama Clinical Site1, Hidaka

RECRUITING

Saitama Clinical Site2, Kitaadachi-gun

RECRUITING

Tokyo Clinical Site3, Bunkyo-ku

RECRUITING

Tokyo Clinical Site2, Chuo-ku

RECRUITING

Tokyo Clinical Site1, Koto-ku

RECRUITING

Tokyo Clinical Site4, Shinjuku-ku

RECRUITING

Chiba Clinical Site2, Chiba

RECRUITING

Fukuoka Clinical Site2, Fukuoka

RECRUITING

Fukuoka Clinical Site3, Fukuoka

RECRUITING

Hiroshima Clinical Site1, Hiroshima

RECRUITING

Kyoto Clinical Site1, Kyoto

RECRUITING

Okayama Clinical Site1, Okayama

RECRUITING

Osaka Clinical Site2, Osaka

RECRUITING

Daegu Clinical Site1, Daegu

RECRUITING

Gyeonggi-do Clinical site1, Gyeonggi-do

RECRUITING

Incheon Clinical Site1, Incheon

RECRUITING

Seoul Clinical Site1, Seoul

COMPLETED

Seoul Clinical Site2, Seoul

RECRUITING

Seoul Clinical Site3, Seoul

RECRUITING

Seoul Clinical Site4, Seoul

RECRUITING

Seoul Clinical Site5, Seoul

RECRUITING

Seoul Clinical Site6, Seoul

COMPLETED

Kaohsiung Clinical Site1, Kaohsiung City

COMPLETED

Kaohsiung Clinical Site2, Kaohsiung City

RECRUITING

Tainan Clinical Site1, Tainan City

RECRUITING

Tainan Clinical Site2, Tainan City

RECRUITING

Taipei Clinical Site1, Taipei

RECRUITING

Taipei Clinical Site2, Taipei

RECRUITING

Taoyuan Clinical Site1, Taoyuan District

Sponsors
All Listed Sponsors
lead

Ono Pharmaceutical Co. Ltd

INDUSTRY

NCT04566380 - ONO-4538 Phase II Rollover Study (ONO-4538-98) | Biotech Hunter | Biotech Hunter